Abstract
BackgroundAutologous Matrix-Induced Chondrogenesis (AMIC) is addressed to osteochondral defects of the talus. However, evidence concerning the midterm efficacy and safety of AMIC are limited. This study assessed reliability and feasibility of AMIC at 60 months follow-up. We hypothesize that AMIC leads to good clinical outcome at midterm follow-up.MethodsSurgeries were approached with an arthrotomy via malleolar osteotomy. A resorbable porcine I/III collagen membrane (Chondro-Gide®, Geistlich Pharma AG, Wolhusen, Switzerland) was used. Patients were followed at 24 and 60 months. The primary outcome of interest was to analyse the Foot Function Index (FFI), and the subscale hindfoot of the American Orthopaedic Foot and Ankle Score (AOFAS). Complications such as failure, revision surgeries, graft delamination, and hypertrophy were also recorded. The secondary outcome of interest was to investigate the association between the clinical outcome and patient characteristics at admission.ResultsData from 19 patients were included. The mean age at admission was 47.3 ± 13.2 years, and the mean BMI 24.1 ± 4.9 kg/m2. 53% (10 of 19 patients) were female. At a mean of 66.2 ± 11.6 months, the FFI decreased at 24-months follow-up of 22.5% (P = 0.003) and of further 1.3% (P = 0.8) at 60-months follow-up. AOFAS increased at 24-months follow-up of 17.2% (P = 0.003) and of further 3.4 (P = 0.2) at 60-months follow-up. There were two symptomatic recurrences within the follow-up in two patients. There was evidence of a strong positive association between FFI and AOFAS at baseline and the same scores last follow-up (P = 0.001 and P = 0.0002, respectively).ConclusionAMIC enhanced with cancellous bone graft demonstrated efficacy and feasibility for osteochondral defects of the talus at five years follow-up. The greatest improvement was evidenced within the first two years. These results suggest that clinical outcome is influenced by the preoperative status of the ankle. High quality studies involving a larger sample size are required to detect seldom complications and identify prognostic factors leading to better clinical outcome.Level of evidenceII, prospective cohort study.
Highlights
Up to 50% of patients who experienced an acute ankle sprain demonstrated chondral damage [1]
Autologous Matrix-Induced Chondrogenesis (AMIC) is a one-step surgical strategy which exploit the potential of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) [5, 6]
American Orthopaedic Foot and Ankle Score (AOFAS) increased at 24-months follow-up of 17.2% (P = 0.003) and of further 3.4 (P = 0.2) at 60-months follow-up (Table 3)
Summary
Up to 50% of patients who experienced an acute ankle sprain demonstrated chondral damage [1]. Several studies which focused on AMIC for chondral defects of the talus demonstrated high rate of patient satisfaction [10,11,12,13,14,15,16,17,18,19,20,21,22,23,24]. We published our results of AMIC on a cohort of 24 patients for chondral defects of the talus [5]. The present study assessed reliability and feasibility of AMIC on the same cohort of patients at 60 months follow-up. Autologous Matrix-Induced Chondrogenesis (AMIC) is addressed to osteochondral defects of the talus. This study assessed reliability and feasibility of AMIC at 60 months follow-up. We hypothesize that AMIC leads to good clinical outcome at midterm follow-up
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
